Dose-related effects of motilin on proximal gastrointestinal motility
Authors: Kamerling, I. M. C.1; Van Haarst, A. D.1; Burggraaf, J.1; Schoemaker, H. C.1; Biemond, I.2; Jones, R.3; Cohen, A. F.1; Masclee, A. A. M.2
Source: Alimentary Pharmacology & Therapeutics, Volume 16, Number 1, January 2002 , pp. 129-135(7)
Publisher: Blackwell Publishing
Abstract:
Aim: To assess non-invasively the dose-response relations for the effects of exogenous motilin on antrum contraction frequency, gall-bladder volume and gastric myoelectrical activity. Methods: In a double-blind, randomized, placebo-controlled, five-way crossover study, 10 fasted healthy volunteers were infused intravenously with synthetic human motilin (0.5, 1, 2 and 4 pmol.min/kg) or placebo for 60 min. Gall-bladder volume and antrum contractions were assessed by ultrasonography and gastric myoelectrical activity by electrogastrography. Motilin concentrations were measured using a radioimmunoassay. Results: Baseline plasma motilin levels (60 pmol/L) were similar for all treatments. Motilin levels increased upon the start of infusion and rapidly returned to baseline after cessation of the infusion. At motilin doses of 2 and 4 pmol.min/kg, the antrum contraction frequency was significantly augmented, with maximum differences of two contractions per 2-min interval compared to placebo, while no changes in gastric myoelectrical activity were observed. Changes in gall-bladder volume were not significantly different for any of the motilin doses compared to placebo. Conclusions: Motilin increased antrum contraction frequency, whereas no effect on gastric myoelectrical activity was observed. Antrum contraction frequency appears to be a useful biomarker for motilin efficacy, and motilin doses of 2 and 4 pmol.min/kg were equally effective.Document Type: Research article
DOI: 10.1046/j.1365-2036.2002.01142.x
Affiliations: 1: Centre for Human Drug Research, Leiden, The Netherlands, 2: Leiden University Medical Centre, Department of Gastroenterology, Leiden, The Netherlands, 3: R. W. Johnson Pharmaceutical Research Institute, High Wycombe, UK

Click here for Page Help